Five things for pharma marketers to know: Tuesday, September 26, 2017

Share this content:


1. The Justice Department contacted Patient Services, which helps patients pay the out-of-pocket costs of drugs, in connection with a probe into the marketing of Aegerion Pharmaceuticals' cholesterol-lowering drug Juxtapid. Aegerion plead guilty to misbranding charges and will pay more than $35 million to resolve those allegations. (Reuters)

2. The most heavily promoted drugs in Canada were found to have little therapeutic value, according to a new study. Researchers said that the study questions whether doctors should read journal ads or seek sales reps for more information about promoted drugs. (CMAJ)

3. Allergan received a refusal-to-file letter from the FDA for a supplemental new drug application for its schizophrenia drug, Vraylar, for an indication that would allow the drugmaker to market it as a treatment for negative symptoms of schizophrenia.

4. The FDA said clinical-trial results of PTC Therapeutics' experimental Duchenne muscular dystrophy drug, ataluren, were “clearly negative.” An advisory committee meeting is scheduled for Thursday. (Endpoints News)

5. ICYMI: AbbVie CEO Richard Gonzalez believes that criticism of high drug prices is waning, and the company “sees little risk of significant changes in drug price regulation in the U.S.” (Axios)

Share this content:
Scroll down to see the next article